Rani Therapeutics Holdings RANI
NASDAQ RANI
$0.84 +0.02 (+2.51%)
At close: Sep 11, 2026 · 4:00 PM EDT

Rani Therapeutics Holdings (RANI) Other Non-Current Assets (2021 - 2026)

Rani Therapeutics Holdings (RANI) posted Other Non-Current Assets of $246000.0 for Q2 2026, little changed on a QoQ basis from $246000.0 in Q1 2026, and down 16.04% year-over-year from $293000.0 in Q2 2025.

Analysis

Rani Therapeutics Holdings (RANI) Other Non-Current Assets (2021 - 2026) Analysis & Trends

Rani Therapeutics Holdings has reported Other Non-Current Assets for 6 years, with the latest figure at $246000.0 in Q2 2026.

  • On a quarterly basis, Other Non-Current Assets fell 16.04% year-over-year to $246000.0 in Q2 2026; TTM through Jun 2026 was $246000.0, a 16.04% decrease from a year earlier, with the FY2025 full-year figure at $246000.0, changed 0.0% from the prior year.
  • Other Non-Current Assets was $246000.0 for Q2 2026 at Rani Therapeutics Holdings, roughly flat from $246000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $500000.0 in Q3 2022, with the low at $245000.0 in Q3 2025.
  • Average Other Non-Current Assets over 5 years is $271000.0, with a median of $246000.0 recorded in 2023.
  • The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets gained 19.11% in 2025, then decreased 16.04% in 2026.
  • Over 5 years, Other Non-Current Assets stood at $500000.0 in 2022, then slumped by 50.8% to $246000.0 in 2023, then changed by 0.0% to $246000.0 in 2024, then changed by 0.0% to $246000.0 in 2025, then changed by 0.0% to $246000.0 in 2026.
  • The last three Other Non-Current Assets figures came in at $246000.0 (Q2 2026), $246000.0 (Q1 2026), and $246000.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 12.98 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 4.75 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 2.31 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 124.00 Mn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 618.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 65.13 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 831.80 Mn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 29.59 Mn
10 Rani Therapeutics Holdings 157.97 Mn 157.97 Mn - 246,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 246,000.00
Mar 31, 2026 246,000.00
Dec 31, 2025 246,000.00
Sep 30, 2025 245,000.00
Jun 30, 2025 293,000.00
Mar 31, 2025 246,000.00
Dec 31, 2024 246,000.00
Sep 30, 2024 246,000.00
Jun 30, 2024 246,000.00
Mar 31, 2024 246,000.00
Dec 31, 2023 246,000.00
Sep 30, 2022 500,000.00
Jun 30, 2021 3.41 Mn